Skip to main content
SpringerLink
Log in

Guidelines and recommendations for use

  • Chapter
  • First Online:
Handbook of Incretin-based Therapies in Type 2 Diabetes

  • 523 Accesses

Abstract

Incretin-based therapies now play an important role in the treatment of type 2 diabetes mellitus. The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) 2015 algorithm and the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) 2015 Position Statement highlight the benefit of a patient-centered approach that encourages individualized therapy and use of medications that do not add to the disease burden, specifically with further weight gain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 Executive Summary. Endocr Pract. 2015;21:413-437.

    Google Scholar 

  2. Garber A, Abrahamson MJ, Brazilay JI, Blonde L, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive diabetes management algorithm 2015. Endoc Pract. 2015; 21: 438-447.

    Google Scholar 

  3. Inzucchi SE, Berganstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.

    Google Scholar 

  4. International Diabetes Federation (IDF). IDF Clinical Guidelines (2011/2012): Global Guidelines for Type 2 Diabetes. www.idf.org/guidelines. Accessed October 10, 2015.

  5. National Institute for Health and Care Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes (2009): Clinical Guideline 87. www.nice.org.uk/guidance/cg87. Accessed October 10, 2015.

  6. National Institute for Health and Care Excellence (NICE). Blood-glucose lowering therapy in type 2 diabetes. http://pathways.nice.org.uk/pathways/diabetes/blood-glucose-lowering therapy-for-type-2-diabetes.xml. Accessed October 10, 2015.

  7. Electronic Medicines Compendium. Januvia SPC. www.medicines.org.uk/emc/medicine/19609/SPC. Accessed October 10, 2015.

  8. European Medicines Agency. Summary of Product Characteristics. Januvia 25 mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Accessed October 10, 2015.

  9. Food and Drug Administration (FDA). Highlights of prescibing information. Januvia (sitagliptin). www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s033lbl.pdf. Updated March 2015. Accessed October 10, 2015.

  10. Electronic Medicines Compendium. Onglyza SPC. www.medicines.org.uk/emc/medicine/22315/SPC. Accessed October 10, 2015.

  11. European Medicines Agency. Summary of Product Characteristics. Onglyza 2.5 mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf. Accessed October 10, 2015.

  12. Food and Drug Administration (FDA). Highlights of prescibing information. Onglyza (saxagliptin). www.accessdata.fda.gov/drugsatfda_docs/label/2013/022350s011lbl.pdf. Updated May 2013. Accessed August 10, 2015.

  13. Electronic Medicines Compendium. Vipidia SPC. www.medicines.org.uk/emc/medicine/28513/SPC. Accessed August 10, 2015.

  14. European Medicines Agency. Summary of Product Characteristics. Vipidia 6.25. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002182/WC500152271.pdf. Accessed August 10, 2015.

  15. Food and Drug Administration (FDA). Highlights of prescibing information. Vipidia (alogliptin). www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Updated January 2013. Accessed October 10, 2015.

  16. Electronic Medicines Compendium. Galvus SPC. www.medicines.org.uk/emc/medicine/20734/SPC. Accessed October 10, 2015.

  17. European Medicines Agency. Summary of product characteristics. Galvus 50 mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Accessed October 10, 2015.

  18. Electronic Medicines Compendium. Trajenta SPC. www.medicines.org.uk/emc/medicine/25000/SPC. Accessed October 10, 2015.

  19. European Medicines Agency. Summary of product characteristics. Trajenta 5 mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Accessed October 10, 2015.

  20. Food and Drug Administration. Highlights of prescibing information. Tradjenta (linagliptin). www.accessdata.fda.gov/drugsatfda_docs/label/2015/201280s011lbl.pdf. Updated July 2015. Accessed October 10, 2015.

  21. Electronic Medicines Compendium. Byetta SPC. www.medicines.org.uk/emc/medicine/19257. Accessed October 10, 2015.

  22. European Medicines Agency. Summary of product characteristics. Byetta 5 μg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf. Accessed October 10, 2015.

  23. Food and Drug Administration (FDA). Highlights of prescribing information. Byetta (exenatide). www.accessdata.fda.gov/drugsatfda_docs/label/2015/021773s040lbl.pdf. Updated February 2015. Accessed October 10, 2015.

  24. Electronic Medicines Compendium. Lyxumia SPC. www.medicines.org.uk/emc/medicine/27405. Accessed October 10, 2015.

  25. European Medicines Agency. Summary of product characteristics. Lyxumia 10 μg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf. Accessed October 10, 2015.

  26. Electronic Medicines Compendium. Victoza SPC. www.medicines.org.uk/emc/medicine/21986. Accessed October 10, 2015.

  27. European Medicines Agency. Summary of product characteristics. Victoza 6 mg/ml. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Accessed October 10, 2015.

  28. Food and Drug Administration (FDA). Highlights of prescribing information. Victoza (liraglutide). www.accessdata.fda.gov/drugsatfda_docs/label/2015/022341s023lbl.pdf. Updated March 2015. Accessed October 10, 2015.

  29. Electronic Medicines Compendium. Bydureon SPC. www.medicines.org.uk/emc/medicine/24665. Accessed October 10, 2015.

  30. European Medicines Agency. Summary of product characteristics. Bydureon 2mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf. Accessed October 10, 2015.

  31. Food and Drug Administration (FDA). Highlights of prescribing information. Bydueron (exenatide extended release). www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s019lbl.pdf. Accessed October 10, 2015.

  32. Electronic Medicines Compendium. Trulicity SPC. www.medicines.org.uk/emc/medicine/29747. Accessed October 10, 2015.

  33. European Medicines Agency. Summary of product characteristics. Trulicity 0.75mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf. Accessed October 10, 2015.

  34. Food and Drug Administration (FDA). Highlights of prescribing information. Trulicity (dulaglutide). www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf. Updated Sept 2014. Accessed October 10, 2015.

  35. European Medicines Agency. Summary of product characteristics. Eperzan 30 mg. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf. Accessed October 10, 2015.

  36. Food and Drug Administration. Highlights of prescribing information. Tanzeum (albiglutide). www.accessdata.fda.gov/drugsatfda_docs/label/2015/125431s009lbl.pdf. Updated May 2015. Accessed October 10, 2015.

Download references

Author information

Authors and Affiliations

  1. University of Oxford, Oxford, UK

    Archana Dhere & Stephen C. L. Gough

Authors
  1. Archana Dhere
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen C. L. Gough
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oxford Ctre for Diabe, Endocrngy & Metab, Oxford University, Oxford, Oxfordshire, United Kingdom

    Stephen Gough

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dhere, A., Gough, S.C.L. (2016). Guidelines and recommendations for use. In: Gough, S. (eds) Handbook of Incretin-based Therapies in Type 2 Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-08982-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08982-9_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08981-2

  • Online ISBN: 978-3-319-08982-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation